Cargando…
Optimization of the biotechnological production of a novel class of anti-MRSA antibiotics from Chitinophaga sancti
BACKGROUND: Recently, the discovery of the elansolids, a group of macrolides, was reported. The molecules show activity against methicillin-resistant Staphylococcus aureus as well as other gram-positive organisms. This fact renders those substances a promising starting point for future chemical deve...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5561589/ https://www.ncbi.nlm.nih.gov/pubmed/28818083 http://dx.doi.org/10.1186/s12934-017-0756-z |
_version_ | 1783257857269956608 |
---|---|
author | Beckmann, Amelie Hüttel, Stephan Schmitt, Viktoria Müller, Rolf Stadler, Marc |
author_facet | Beckmann, Amelie Hüttel, Stephan Schmitt, Viktoria Müller, Rolf Stadler, Marc |
author_sort | Beckmann, Amelie |
collection | PubMed |
description | BACKGROUND: Recently, the discovery of the elansolids, a group of macrolides, was reported. The molecules show activity against methicillin-resistant Staphylococcus aureus as well as other gram-positive organisms. This fact renders those substances a promising starting point for future chemical development. The active atropisomers A1/A2 are formed by macrolactonization of the biosynthesis product A3 but are prone to ring opening and subsequent formation of several unwanted side products. Recently it could be shown that addition of different nucleophiles to culture extracts of Chitinophaga sancti enable the formation of new stable elansolid derivatives. Furthermore, addition of such a nucleophile directly into the culture led exclusively to formation of a single active elansolid derivative. Due to low product yields, methods for production of gram amounts of these molecules have to be established to enable further development of this promising compound class. RESULTS: Production of elansolid A2 by C. sancti was enabled using a synthetic medium with sucrose as carbon source to a final concentration of 18.9 mg L(−1). A fed-batch fermentation was ensued that resulted in an elansolid A2 concentration of 55.3 mg L(−1). When using glucose as carbon source in a fed-batch fermentation only 34.4 mg L(−1) elansolid A2 but 223.1 mg L(−1) elansolid C1 were produced. This finding was not unexpected since elansolids A1/A2 and A3 have been reported to easily react with nucleophiles like anthranilic acid, a precursor of tryptophan biosynthesis. Due to the fact that nucleophiles can be incorporated in vivo, a fed-batch cultivation under identical conditions, with addition of anthranilic acid was carried out and lead to almost exclusive formation of elansolid C1 (257.5 mg L(−1)). CONCLUSION: Reproducible elansolid A2 and C1 production is feasible in different synthetic media at relatively high concentrations that will allow further investigation and semi-synthetic optimization. The feeding of anthranilic acid enables the exclusive production of the stable elansolid derivative C1, which reduces product loss by unspecific reactions and eases downstream processing. This derivative shows activity in the same range as the elansolids A1/A2. Hence, the method can possibly serve as a model-process for incorporation of other nucleophiles and biotechnological production of specifically designed molecules. |
format | Online Article Text |
id | pubmed-5561589 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-55615892017-08-18 Optimization of the biotechnological production of a novel class of anti-MRSA antibiotics from Chitinophaga sancti Beckmann, Amelie Hüttel, Stephan Schmitt, Viktoria Müller, Rolf Stadler, Marc Microb Cell Fact Research BACKGROUND: Recently, the discovery of the elansolids, a group of macrolides, was reported. The molecules show activity against methicillin-resistant Staphylococcus aureus as well as other gram-positive organisms. This fact renders those substances a promising starting point for future chemical development. The active atropisomers A1/A2 are formed by macrolactonization of the biosynthesis product A3 but are prone to ring opening and subsequent formation of several unwanted side products. Recently it could be shown that addition of different nucleophiles to culture extracts of Chitinophaga sancti enable the formation of new stable elansolid derivatives. Furthermore, addition of such a nucleophile directly into the culture led exclusively to formation of a single active elansolid derivative. Due to low product yields, methods for production of gram amounts of these molecules have to be established to enable further development of this promising compound class. RESULTS: Production of elansolid A2 by C. sancti was enabled using a synthetic medium with sucrose as carbon source to a final concentration of 18.9 mg L(−1). A fed-batch fermentation was ensued that resulted in an elansolid A2 concentration of 55.3 mg L(−1). When using glucose as carbon source in a fed-batch fermentation only 34.4 mg L(−1) elansolid A2 but 223.1 mg L(−1) elansolid C1 were produced. This finding was not unexpected since elansolids A1/A2 and A3 have been reported to easily react with nucleophiles like anthranilic acid, a precursor of tryptophan biosynthesis. Due to the fact that nucleophiles can be incorporated in vivo, a fed-batch cultivation under identical conditions, with addition of anthranilic acid was carried out and lead to almost exclusive formation of elansolid C1 (257.5 mg L(−1)). CONCLUSION: Reproducible elansolid A2 and C1 production is feasible in different synthetic media at relatively high concentrations that will allow further investigation and semi-synthetic optimization. The feeding of anthranilic acid enables the exclusive production of the stable elansolid derivative C1, which reduces product loss by unspecific reactions and eases downstream processing. This derivative shows activity in the same range as the elansolids A1/A2. Hence, the method can possibly serve as a model-process for incorporation of other nucleophiles and biotechnological production of specifically designed molecules. BioMed Central 2017-08-17 /pmc/articles/PMC5561589/ /pubmed/28818083 http://dx.doi.org/10.1186/s12934-017-0756-z Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Beckmann, Amelie Hüttel, Stephan Schmitt, Viktoria Müller, Rolf Stadler, Marc Optimization of the biotechnological production of a novel class of anti-MRSA antibiotics from Chitinophaga sancti |
title | Optimization of the biotechnological production of a novel class of anti-MRSA antibiotics from Chitinophaga sancti |
title_full | Optimization of the biotechnological production of a novel class of anti-MRSA antibiotics from Chitinophaga sancti |
title_fullStr | Optimization of the biotechnological production of a novel class of anti-MRSA antibiotics from Chitinophaga sancti |
title_full_unstemmed | Optimization of the biotechnological production of a novel class of anti-MRSA antibiotics from Chitinophaga sancti |
title_short | Optimization of the biotechnological production of a novel class of anti-MRSA antibiotics from Chitinophaga sancti |
title_sort | optimization of the biotechnological production of a novel class of anti-mrsa antibiotics from chitinophaga sancti |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5561589/ https://www.ncbi.nlm.nih.gov/pubmed/28818083 http://dx.doi.org/10.1186/s12934-017-0756-z |
work_keys_str_mv | AT beckmannamelie optimizationofthebiotechnologicalproductionofanovelclassofantimrsaantibioticsfromchitinophagasancti AT huttelstephan optimizationofthebiotechnologicalproductionofanovelclassofantimrsaantibioticsfromchitinophagasancti AT schmittviktoria optimizationofthebiotechnologicalproductionofanovelclassofantimrsaantibioticsfromchitinophagasancti AT mullerrolf optimizationofthebiotechnologicalproductionofanovelclassofantimrsaantibioticsfromchitinophagasancti AT stadlermarc optimizationofthebiotechnologicalproductionofanovelclassofantimrsaantibioticsfromchitinophagasancti |